Can Patients Switch to Biosimilar Aflibercept? - Top-Institutions - MDSpire

Can Patients Switch to Biosimilar Aflibercept?

A 20-week INSIGHT extension suggests that switching from reference aflibercept to MYL-1701P maintained comparable safety, visual, and anatomic outcomes in patients with diabetic macular edema.

  • By

  • Andrea Surnit

  • July 20, 2026

  • 3 min

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    Rising Retina Clinic
    Rising Retina Clinic

    Unknown, Unknown

    Key Differentiators

    • Ophthalmology

  • #2

    Retina Consultants of Texas
    Retina Consultants of Texas

    Unknown, Unknown

    Key Differentiators

    • Ophthalmology

  • #3

    University of Chicago
    University of Chicago

    Chicago, IL

    Key Differentiators

    • Ophthalmology

  • #4

    Michigan Retina Center
    Michigan Retina Center

    Unknown, Unknown

    Key Differentiators

    • Ophthalmology

  • #5

    Retinal Consultants of Arizona
    Retinal Consultants of Arizona

    Unknown, Unknown

    Key Differentiators

    • Ophthalmology

Original Source(s)

Can Patients Switch to Biosimilar Aflibercept?

  • by Andrea Surnit

  • July 20, 2026

Related Content

Marked and reversible circulating insulin-like growth factor-1 elevation during teprotumumab N01 treatment for thyroid eye disease with limited correspondence to glycemic changes

Phenotype-driven management of diabetic macular edema: multimodal imaging biomarkers and individualized therapy

Diabetes Risk Scores: Beyond Glucose

Multi-ancestry polygenic models identify high-risk patients traditional screening may miss.